This is important because GDF5 has been proposed as a candidate neurotrophic factor for therapeutic application in PD (O’Keeffe et al., 2017; Paul and Sullivan, 2018), where a characteristic feature is axonal degeneration (Burke and O'Malley, 2013; O'Keeffe and Sullivan, 2018). This evidence concerns the gene GDF5 and Parkinson disease.